Cardiac stem cells in ischemic cardiomyopathy – an update of SCIPIO trial
Cardiac diseases can provide a huge potential market for cell therapies. There are 2 key components for success: (i) unmet medical need and (ii) large patients population. That’s why many companies are...
View ArticleThe biggest scandal in cell therapy
In the last decade, we have been witnessing many scandals and lots of scam in stem cell research. The field is very hot and filled with a hype. Well, it seem like cell therapy field (which is all about...
View ArticleClik here to view.
Some thoughts on results of NeoStem cardiac cell therapy trial
In the last two days I was involved in lively twitter discussions about the results of Phase 2 PreSERVE-AMI clinical trial, sponsored by NeoStem. Unfortunately, interpretation of results divided...
View ArticleClik here to view.
Cell therapy clinical trials failures in 2014
Today, I’d like to highlight the most interesting, in my opinion, clinical trials failures, reported in 2014. As field is moving to efficacy (Phase 2) trials, we are starting to see more failures. In...
View Article
